Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Assets: 2014-2025

Historic Assets for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to $739.4 million.

  • Viking Therapeutics' Assets fell 21.16% to $739.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $739.4 million, marking a year-over-year decrease of 21.16%. This contributed to the annual value of $908.3 million for FY2024, which is 146.50% up from last year.
  • Per Viking Therapeutics' latest filing, its Assets stood at $739.4 million for Q3 2025, which was down 10.68% from $827.9 million recorded in Q2 2025.
  • Over the past 5 years, Viking Therapeutics' Assets peaked at $967.5 million during Q1 2024, and registered a low of $150.9 million during Q1 2023.
  • Moreover, its 3-year median value for Assets was $827.9 million (2025), whereas its average is $681.6 million.
  • As far as peak fluctuations go, Viking Therapeutics' Assets fell by 25.75% in 2022, and later surged by 541.19% in 2024.
  • Viking Therapeutics' Assets (Quarterly) stood at $210.7 million in 2021, then fell by 20.00% to $168.5 million in 2022, then soared by 118.65% to $368.5 million in 2023, then soared by 146.50% to $908.3 million in 2024, then decreased by 21.16% to $739.4 million in 2025.
  • Its last three reported values are $739.4 million in Q3 2025, $827.9 million for Q2 2025, and $867.0 million during Q1 2025.